Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/03/2005CA2536918A1 Serine protease inhibitors for treatment of bacterial infections
03/03/2005CA2536816A1 Method for deterring abuse of opioids by combination with non-release formulation of emetic
03/03/2005CA2536764A1 .alpha.-aminoamide derivatives useful as anti-inflammatory agents
03/03/2005CA2536654A1 Anti-cancer vaccines
03/03/2005CA2536480A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005CA2536435A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005CA2536422A1 Use of colipase-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity
03/03/2005CA2536414A1 Novel formulation of ropinirole
03/03/2005CA2536349A1 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
03/03/2005CA2536340A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
03/03/2005CA2536293A1 Methods of treating copd and pulmonary hypertension
03/03/2005CA2536288A1 Cancer metastasis inhibitor
03/03/2005CA2536280A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2536275A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005CA2536173A1 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/03/2005CA2536112A1 Methods for enhancing embryo viability
03/03/2005CA2536095A1 Aminobenzimidazole derivatives
03/03/2005CA2536089A1 Ppar modulators
03/03/2005CA2536086A1 Inhibition of dr3 in the treatment of allergic lung inflammation
03/03/2005CA2536053A1 Powder formulation comprising the cgrp antagonist 1-(n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine
03/03/2005CA2536050A1 Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
03/03/2005CA2536048A1 Microparticles comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine method for production and use thereof as inhalation powder
03/03/2005CA2536047A1 Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant
03/03/2005CA2535960A1 Indoline derivatives
03/03/2005CA2535944A1 Blockade of mtor to prevent a hormonal adaptive response
03/03/2005CA2535814A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal
03/03/2005CA2535813A1 Pantoprazole preparation for injection
03/03/2005CA2535811A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005CA2535810A1 Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethylester or the salts thereof
03/03/2005CA2535803A1 Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
03/03/2005CA2535802A1 Novel sulfenamides
03/03/2005CA2535800A1 Novel sulfenamide oxides
03/03/2005CA2535796A1 N-aryl-2-cyanooxazolidinones and their derivatives
03/03/2005CA2535771A1 Use of melatonin-containing oral supplement with animals
03/03/2005CA2535745A1 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005CA2535714A1 Phenoxyacetic acid derivatives
03/03/2005CA2535644A1 Substituted pyrimdinone derivatives and methods of use
03/03/2005CA2535585A1 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
03/03/2005CA2535583A1 Method of inducing immune tolerance
03/03/2005CA2535571A1 Composition for treatment of tinea pedis and method of use
03/03/2005CA2535550A1 Treatment for acne vulgaris and method of use
03/03/2005CA2535516A1 Silencing of tgf-beta receptor type ii expression by sirna
03/03/2005CA2535359A1 Cathepsin cysteine protease inhibitors
03/03/2005CA2535350A1 Acetylene derivatives as inhibitors of histone deacetylase
03/03/2005CA2535347A1 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
03/03/2005CA2535341A1 (4-hydroxyphenyl)-1h-indole-3-carbaldehyde oxime derivative as estrogenic agents
03/03/2005CA2535337A1 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
03/03/2005CA2535185A1 2-methylene-19-nor-vitamin d2 compounds
03/03/2005CA2535120A1 Hydroxylamine substituted imidazo-containing compounds
03/03/2005CA2535117A1 Oxime substituted imidazo-containing compounds
03/03/2005CA2535063A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005CA2534941A1 Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
03/03/2005CA2533895A1 Methods of reducing risk of infection from pathogens
03/03/2005CA2533890A1 Compounds for the treatment of metabolic disorders
03/03/2005CA2533889A1 Mitotic kinesin inhibitors
03/03/2005CA2533435A1 Mitotic kinesin inhibitors
03/03/2005CA2533396A1 3-aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
03/03/2005CA2533126A1 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
03/03/2005CA2533112A1 Melanin concentrating hormone receptor antagonist
03/03/2005CA2532020A1 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
03/03/2005CA2531146A1 Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
03/03/2005CA2529647A1 Influenza hemagglutinin and neuraminidase variants
03/03/2005CA2529401A1 Processes for preparing 3-benzazepines
03/03/2005CA2528089A1 Biaryl heterocyclic compounds and methods of making and using the same
03/03/2005CA2526431A1 Compositions and methods for treatment of severe acute respiratory syndrome (sars)
03/03/2005CA2523658A1 Rnai agents for anti-sars coronavirus therapy
03/02/2005EP1510521A1 Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
03/02/2005EP1510519A1 Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510516A1 Pyrazole compound and medicinal composition containing the same
03/02/2005EP1510515A1 Phenylglycine derivatives as serine protease inhibitors
03/02/2005EP1510225A2 Photochemotherapeutic and diagnostic application using 5-ALA and precursors
03/02/2005EP1510223A1 Intravenous composition, process for producing the same and preparation thereof
03/02/2005EP1510222A2 Medicinal compositions promoting bowel movement
03/02/2005EP1510221A1 Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
03/02/2005EP1510220A1 Therapeutic inhibitor of vascular smooth muscle cells
03/02/2005EP1510219A1 Method for identifying at least one Aminopeptidase-inhibitor
03/02/2005EP1510217A1 An anti-rheumatism medicament and method to prepare thereof
03/02/2005EP1510215A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same
03/02/2005EP1510214A2 8a-azalides as veterinary antimicrobial agents
03/02/2005EP1510213A2 Penetration enhancing and irritation reducing systems comprising testosterone
03/02/2005EP1510212A1 Use of 4-substituted-quinazoline derivatives for producing therapeutic agents
03/02/2005EP1510211A1 Pharmaceutical composition comprising N-retinyl-N-retinylidene Ethanolamine (A2E), isoforms of A2E or derivatives thereof
03/02/2005EP1510210A1 Immunity-related protein kinase inhibitors
03/02/2005EP1510209A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
03/02/2005EP1510208A1 Pharmaceutical composition comprising a combination of metformin and statin
03/02/2005EP1510207A1 Therapeutic drug for diabetes
03/02/2005EP1510206A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/02/2005EP1510205A1 Universal controlled-release composition comprising xanthan gum and sodium alginate
03/02/2005EP1510137A1 Pyruvate enriched onion extract
03/02/2005EP1510136A1 Process for producing lacturose-containing powder composition, lacturose-containing powder composition obtained by the process and feed additive
03/02/2005EP1509772A2 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2)
03/02/2005EP1509768A2 Methods for cohort selection and longevity studies
03/02/2005EP1509618A2 Autoimmune conditions and nadph oxidase defects
03/02/2005EP1509607A1 Immunogenic sequences
03/02/2005EP1509606A1 Allergen from mugwort pollen
03/02/2005EP1509598A2 Induction of insulin expression
03/02/2005EP1509549A1 Extraction of unmilled psyllium
03/02/2005EP1509538A1 6,11 bicyclic erythromycin derivatives
1 ... 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 4786 4787 4788 ... 7860